<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03574571</url>
  </required_header>
  <id_info>
    <org_study_id>18-150</org_study_id>
    <secondary_id>2018-002944-10</secondary_id>
    <nct_id>NCT03574571</nct_id>
  </id_info>
  <brief_title>A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer</brief_title>
  <official_title>Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare any good and bad effects of using radium-223 along&#xD;
      with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped&#xD;
      show that the combination is safe, but the combination has not been proven to work better&#xD;
      than either drug alone. The goal of this study is to find out if combining docetaxel and&#xD;
      radium-223 is better than giving either drug by itself.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an open-labeled, randomized, phase III study of docetaxel versus docetaxel in combination with radium-223 in subjects with mCRPC.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival is defined as the time from randomization to death from any cause.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">738</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses. Prednisone will be given at a dose of 5mg orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel with Radium-223</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses. Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel 75 mg/m2</intervention_name>
    <description>Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel 60 mg/m2</intervention_name>
    <description>Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.</description>
    <arm_group_label>Docetaxel with Radium-223</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223</intervention_name>
    <description>Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.</description>
    <arm_group_label>Docetaxel with Radium-223</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent (ICF) and HIPAA authorization for&#xD;
             the release of personal health information. A signed informed consent must be obtained&#xD;
             before screening procedures are performed.&#xD;
&#xD;
        NOTE: HIPAA authorization may be either included in the informed consent or obtained&#xD;
        separately.&#xD;
&#xD;
          -  Males 18 years of age and above&#xD;
&#xD;
          -  Histological or cytological proof of prostate cancer&#xD;
&#xD;
          -  Documented progressive mCRPC based on at least one of the following criteria:&#xD;
&#xD;
               1. PSA progression defined as 25% increase over baseline value with an increase in&#xD;
                  the absolute value of at least 1.0 ng/mL that is confirmed by another PSA level&#xD;
                  with a minimum of a 1 week interval and a minimum PSA of 1.0 ng/mL.&#xD;
&#xD;
               2. Soft-tissue progression defined as an increase ≥ 20% in the sum of the LD of all&#xD;
                  target lesions based on the smallest sum LD since treatment started or the&#xD;
                  appearance of one or more new lesions.&#xD;
&#xD;
               3. Progression of bone disease (evaluable disease) or two or more new bone lesions&#xD;
                  by bone scan.&#xD;
&#xD;
          -  Two or more bone lesions&#xD;
&#xD;
          -  ECOG 0- 1&#xD;
&#xD;
          -  Normal organ function with acceptable initial laboratory values within 14 days of&#xD;
             randomization:&#xD;
&#xD;
               -  Albumin &gt; 30 g/L&#xD;
&#xD;
               -  ANC ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
               -  Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  Bilirubin ≤ ULN (unless documented Gilbert's disease)&#xD;
&#xD;
               -  SGOT (AST) ≤ 1.5 x ULN&#xD;
&#xD;
               -  SGPT (ALT) ≤ 1.5 x ULN&#xD;
&#xD;
               -  WBC count ≥ 3 x 10^9/L&#xD;
&#xD;
          -  Subjects must agree to use a medically acceptable method of birth control (e.g.,&#xD;
             spermicide in conjunction with a barrier such as a condom) or sexual abstinence for&#xD;
             the duration of the study, including 30 days after the last dose of study drug. Sperm&#xD;
             donation is prohibited during the study and for 30 days after the last dose of study&#xD;
             drug. Female partners must use hormonal or barrier contraception unless postmenopausal&#xD;
             or abstinent.&#xD;
&#xD;
          -  Serum testosterone &lt; 50 ng/dL. Subjects must continue primary androgen deprivation&#xD;
             with an LHRH analogue (agonist or antagonist) if they have not undergone orchiectomy.&#xD;
&#xD;
          -  All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v4.0 Grade 1&#xD;
             or less.&#xD;
&#xD;
          -  Willing and able to comply with the protocol, including follow-up visits and&#xD;
             examinations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received any other investigational therapeutic agents or other anticancer therapies&#xD;
             within 4 weeks prior to randomization.&#xD;
&#xD;
          -  Received external beam radiotherapy within the 4 weeks prior to randomization.&#xD;
&#xD;
          -  Has an immediate need for external beam radiotherapy.&#xD;
&#xD;
          -  Has received any systemic bone-seeking radiopharmaceutical in the past.&#xD;
&#xD;
          -  Has received any prostate cancer directed chemotherapy in the castration resistant&#xD;
             setting. Subjects who have received up to 6 prior doses of docetaxel in the castration&#xD;
             sensitive setting are permitted if they have not experienced disease progression&#xD;
             within 36 weeks of last treatment with docetaxel.&#xD;
&#xD;
          -  Has received four or more systemic anticancer regimens for mCRPC.&#xD;
&#xD;
               -  Treatment with docetaxel or abiraterone for non-castrate metastatic disease is&#xD;
                  permissible and does not count towards the lines of therapy for mCRPC&#xD;
&#xD;
               -  A 'line' is a regimen. Combinations of hormones and other types of therapies&#xD;
                  count as single lines.&#xD;
&#xD;
          -  Has known Grade ≥3 docetaxel-related toxicities or docetaxel toxicity related dose&#xD;
             interruption or discontinuation.&#xD;
&#xD;
          -  Has received blood transfusions or growth factors within the last 4 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Symptomatic nodal disease (i.e., scrotal, penile, or leg edema).&#xD;
&#xD;
          -  Has visceral metastases with ≥ 3 lung and/or liver metastases or individual lesion ≥2&#xD;
             cm, as assessed by CT scan or MRI of the chest/abdomen/pelvis within the last 8 weeks&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Symptomatic loco-regional disease that causes ongoing Grade 3 or Grade 4 urinary or&#xD;
             rectal symptoms.&#xD;
&#xD;
          -  Subjects with a &quot;currently active&quot; second malignancy other than non-melanoma skin&#xD;
             cancers or non-invasive bladder cancers or other in-situ or non-invasive malignancies.&#xD;
             Subjects are not considered to have a &quot;currently active&quot; malignancy if they have&#xD;
             completed therapy and are free of disease for ≥ 3 years.&#xD;
&#xD;
          -  Has imminent or established cord compression based on clinical findings and/or MRI.&#xD;
&#xD;
          -  Known bone marrow dysplasia&#xD;
&#xD;
          -  Has received any of the following in the 4 weeks prior to randomization:&#xD;
             5-alpha-reductase inhibitors, herbal medications, natural hormonally active foods&#xD;
             (e.g., phytoestrogens) or other food supplements known to alter PSA in humans&#xD;
&#xD;
          -  Any other serious illness or medical condition that would, in the opinion of the&#xD;
             investigator, make this protocol unreasonably hazardous, including but not limited to:&#xD;
&#xD;
               -  Uncontrolled infection&#xD;
&#xD;
               -  NYHA III or IV heart failure&#xD;
&#xD;
               -  Crohn's disease or those with ulcerative colitis who have not undergone a&#xD;
                  colectomy&#xD;
&#xD;
               -  Known active infection with HIV, Hepatitis B or Hepatitis C&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Morris, MD</last_name>
    <phone>646-422-4469</phone>
    <email>morrism@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josef Fox, MD</last_name>
    <phone>212-639-7371</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Rao, MD</last_name>
      <email>Santosh.Rao@bannerhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University- Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Hurwitz, MD, MPH, MsC</last_name>
      <phone>877-925-3637</phone>
      <email>Michael.hurwitz@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helen Graham Cancer Center (Christiana Care)</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Guarino, MD</last_name>
      <phone>302-366-1200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boca Raton Regional Hospital</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Koletsky, MD</last_name>
      <phone>561-955-6400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center (Miami)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Cusnir, MD</last_name>
      <phone>305-535-3300</phone>
      <email>Mike.Cusnir@msmc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dian Wang, MD, PhD</last_name>
      <phone>312-942-5751</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nabil Adra, MD</last_name>
      <phone>317-944-5349</phone>
      <email>nadra@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Cancer Institute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Matrana, MD</last_name>
      <phone>504-842-3910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arif Hussain, MD</last_name>
      <phone>410-328-7225</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kriti Mittal, MD, MS</last_name>
      <phone>508-334-3550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GU Research Network / Urology Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Nordquist, MD</last_name>
      <email>drnordquist@gucancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Vogelzang, MD</last_name>
      <phone>702-952-3400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Morris, MD</last_name>
      <phone>646-422-4469</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at Cooper</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Mulvihill, MD</last_name>
      <phone>856-735-6396</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Morris, MD</last_name>
      <phone>646-422-4469</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Morris, MD</last_name>
      <phone>646-422-4469</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pranshu Bansal, MD</last_name>
      <phone>505-842-8171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Pili, MD</last_name>
      <phone>716-898-4328</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Morris, MD</last_name>
      <phone>646-422-4469</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Morris, MD</last_name>
      <phone>646-422-4469</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Morris, MD</last_name>
      <phone>646-422-4469</phone>
    </contact>
    <contact_backup>
      <last_name>Josef Fox, MD</last_name>
      <phone>212-639-7371</phone>
    </contact_backup>
    <investigator>
      <last_name>Michael Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Tagawa, MD</last_name>
      <phone>646-962-2072</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bronx VA Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Fojo, MD, PhD</last_name>
      <phone>718-584-9000</phone>
      <phone_ext>6669</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunkit Fung, MD</last_name>
      <phone>585-275-5823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Morris, MD</last_name>
      <phone>646-422-4469</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Morris, MD</last_name>
      <phone>646-422-4469</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Whang, MD, PhD</last_name>
      <phone>984-974-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atrium Health/ Levine Cancer Institute</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Earle Burgess, MD</last_name>
      <email>Earle.Burgess@atriumhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuchi Gulati, MD FACP</last_name>
      <email>gulatisi@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayton Physicians Network</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Miller, MD, PhD</last_name>
      <phone>937-293-1622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhishek Tripathi, MD</last_name>
      <phone>405-271-4088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MidLantic Urology</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Belkoff, DO</last_name>
      <phone>610-667-3020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lilly, MD</last_name>
      <phone>843-792-9300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Darcourt, MD</last_name>
      <phone>713-441-9948</phone>
      <email>JGDarcourt@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Millennium Physicians</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umang Patel, MD</last_name>
      <phone>281-440-5006</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Noordwest Ziekenhuisgrouep Alkmaar (NWZ)</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Hendriks, MD</last_name>
      <phone>+31 72 5482872</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente (ZGT)</name>
      <address>
        <city>Almelo</city>
        <zip>7609</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I.M. Oving, MD</last_name>
      <phone>+31-887083782</phone>
      <email>researchoncologie@zgt.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <zip>4818</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.M. Westgeet, MD</last_name>
      <email>researchoncologie@amphia.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medical Center</name>
      <address>
        <city>Den Haag</city>
        <zip>2512</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H Helgason, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.L.T. Imholz, MD</last_name>
      <email>a.imholz@dz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tergooi Hospital</name>
      <address>
        <city>Hilversum</city>
        <zip>1213</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.P. van den Berg, MD</last_name>
      <phone>+31-887535153</phone>
      <email>Researchinterne@tergooi.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis (CWZ)</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D.M. Somford, MD</last_name>
      <email>researchurologie@cwz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Cancer Institute</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald de Wit, MD, PhD</last_name>
      <phone>+31-107040704</phone>
      <email>interne.oncologie@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis &amp; Vlietland</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. Hamberg, MD</last_name>
      <phone>+31-104616295</phone>
      <email>oncologietrials@franciscus.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B.C.M. Haberkom, MD</last_name>
      <phone>+31-102911911</phone>
      <email>reson@maasstadziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis (Utrecht)</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelis Hunting, MD</last_name>
      <email>j.hunting@antoniusaiekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala Kliniek</name>
      <address>
        <city>Zwolle</city>
        <zip>8025</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Metin Tascilar, MD</last_name>
      <email>m.tascilar@isala.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radium-223</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>18-150</keyword>
  <keyword>C16-174</keyword>
  <keyword>DORA Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

